Investing.com - GSK Plc (NYSE:GSK)股价下跌5%，此前美国食品药品监督管理局(FDA)咨询专家组投票反对推荐批准该公司的血癌药物Blenrep，理由是认为其风险大于收益。
FDA肿瘤药物咨询委员会以5比3的投票结果反对Blenrep与通用癌症药物Velcade的组合疗法，并以更强烈的7比1的投票结果拒绝将其与百时美施贵宝公司(Bristol Myers Squibb Co.)(NYSE:BMY)的Pomalyst配对使用。
虽然专家组的建议不具约束力，但它对FDA的最终决定有重大影响，最终决定预计将在7月23日前作出。委员会的担忧主要集中在Blenrep可能导致眼部损伤的问题上，关于较低剂量是否能降低这一风险的问题仍未解决。
这一拒绝对GSK重新将Blenrep引入美国市场的努力构成了挫折。此前，该药物在美国和欧洲均被撤回，原因是未能证明其对另一患者群体的现有治疗方法具有优势。
本文由人工智能协助翻译。更多信息，请参见我们的使用条款。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.